Symptomatic Treatment of MS - European Multiple Sclerosis Platform
Symptomatic Treatment of MS - European Multiple Sclerosis Platform
Symptomatic Treatment of MS - European Multiple Sclerosis Platform
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
59. Dieterich M, Straube A, Brandt T, Paulus W, Büttner U (1991) The effects <strong>of</strong> bacl<strong>of</strong>en and cholin-<br />
ergic drugs on upbeat and downbeat nystagmus. J Neurol Neurosurg Psychiatry 54:627-632<br />
60. Di Fabio RP, Soderberg J, Choi T, Hansen CR, Schapiro RT (1998) Extended outpatient rehabilita-<br />
tion: its influence on symptom frequency, fatigue, and functional status for persons with progressive<br />
multiple sclerosis. Arch Phys Med Rehabil 79:141-146<br />
61. DMKG Study Group (2003) Misoprostol in the treatment <strong>of</strong> trigeminal neuralgia associated with<br />
multiple sclerosis. J Neurol 250:542-545<br />
62. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S (1999) Clinical efficacy and safety <strong>of</strong> tolterodine<br />
compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J<br />
Pelvic Floor Dysfunct 10:283-289<br />
63. Duffy JR, Yorkston KM (2003) Medical interventions for spasmodic dysphonia and some related<br />
conditions: a systematic review. J Med Speech Lang Pathol 11: ix-Iviii<br />
64. Dula E, Keating W, Siami PF, Edmonds A, O’Neil J, Buttler S (2000) Efficacy and safety <strong>of</strong> fixed-dose<br />
and dose-optimization regimens <strong>of</strong> sublingual apomorphine versus placebo in men with erectile<br />
dysfunction. The Apomorphine Study Group. Urology 56:130-135<br />
65. Duquette P, Pleines J, du Souich P (1985) Isoniazid for tremor in multiple sclerosis: a controlled<br />
trial. Neurology 35:1772-1775<br />
66. Eccles M, Freemantle N, Mason J (1998) North <strong>of</strong> England evidence based guideline development<br />
project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in<br />
treating the pain <strong>of</strong> degenerative arthritis. The North <strong>of</strong> England Non-Steroidal Anti-Inflammatory<br />
Drug Guideline Development Group. Br Med J 317:526-530<br />
67. Eckford SD, Carter PG, Jackson SR, Penney MD, Abrams P (1995) An open, in-patient incremental<br />
safety and efficacy study <strong>of</strong> desmopressin in women with multiple sclerosis and nocturia. Br J<br />
Urol 76:459-463<br />
68. Eisen GM, Baron TH, Dominitz JA, Faigel DO, Goldstein JL, Johanson JF, Mallery JS, Raddawi HM,<br />
Vargo JJ, Waring JP, Fanelli RD, Wheeler-Harbough J (2002) Complications <strong>of</strong> upper GI endoscopy.<br />
Gastrointest Endosc 55:784-793<br />
69. Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A (2001) Lamotrigine reduces painful diabetic<br />
neuropathy: a randomized, controlled study. Neurology 57:505-509<br />
70. Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C, Beuche W (2002) Botulinum toxin to reduce<br />
saliva flow: selected indications for ultrasound-guided toxin application into salivary glands.<br />
Laryngoscope 112:82-86<br />
71. Enderby P, Emerson J (1996) Speech and language therapy: does it work? BMJ 312:1655-1658<br />
72. Engelsen BA, Gronning M (1997) Epileptic seizures in patients with multiple sclerosis. Is the prognosis<br />
<strong>of</strong> epilepsy underestimated? Seizure 6:377-382<br />
73. <strong>European</strong> <strong>Multiple</strong> <strong>Sclerosis</strong> <strong>Platform</strong> (2004) Recommendations on rehabilitation services for<br />
45 E<strong>MS</strong>P, <strong>Symptomatic</strong> <strong>Treatment</strong> <strong>of</strong> <strong>Multiple</strong> <strong>Sclerosis</strong>, December 2006 - revised in April 2008
Change language